- Home
- SKYE
as 05-30-2025 4:00pm EST
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 80.7M | IPO Year: | N/A |
| Target Price: | $16.60 | AVG Volume (30 days): | 223.6K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $12.11 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Skye Bioscience Inc. Common Stock News
SKYE Breaking Stock News: Dive into SKYE Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Skye Bioscience to Participate in Upcoming Investment Conferences
GlobeNewswire
13 days ago
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
GlobeNewswire
18 days ago
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
19 days ago
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
GuruFocus.com
23 days ago
Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Promising Trial Progress and ...
GlobeNewswire
23 days ago
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
GlobeNewswire
25 days ago
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
GlobeNewswire
a month ago
Skye Bioscience to Participate in May Investment and Medical Conferences
Compare SKYE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SKYE Skye Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.